An arbitration panel ruled Prime did not violate an agreement with Beam when it developed PM647, for which Prime plans to launch a clinical trial.

The RNA silencer Wainua didn't improve outcomes for ATTR-CM patients who were already receiving the standard of care.

The firm will use the proceeds to develop plixorafenib in BRAF-mutant brain tumors and possibly make a regulatory submission.

Current Chemolab equity holders will own approximately 32 percent of the combined company' shares and Scipher equity holders will own 68 percent.

NEW YORK – Houston biopharma company CoRegen said it has received US Food and Drug Administration clearance to begin a Phase I/II trial of CRG-150, an adoptive cell therapy targeting steroid receptor ...

The biotech is tackling common cardiovascular conditions by targeting risk factors like high cholesterol, triglycerides, and ...

The deal involves non-dilutive cash in exchange for royalties, if the gene therapies are approved, and an equity investment from Oberland Capital.

The firm announced it has aligned with the US Food and Drug Administration on the design of the Phase III study, which could support a biologics license application.

NEW YORK – Sanyou Bio and Baiyunshan Xihe are collaborating to develop radiopharmaceuticals for cancer, a move they hope will expand the nuclear medicine industry in China. Through the partnership, ...

NEW YORK – LTZ Therapeutics on Tuesday said the US Food and Drug Administration has cleared an investigational new drug (IND) application, allowing it to begin clinical testing of its bispecific ...